New Tools Can Better Predict Successful Kidney Transplant Outcomes
Study demonstrates potential for improved individualized patient care in living donor kidney transplantation
New York, NY, January 22, 2009 – Kidney transplants are the best available therapy for end stage renal disease. Because of the shortage of deceased organ donors, living donor transplantation is rapidly growing and has the advantage of improved outcomes over deceased donor transplants. In fact, a transplant candidate may now have several potential living donors and the clinician may need to identify which donor would yield the best results. In a study published in the March 2009 issue of The Journal of Urology, researchers report on the development and validation of three nomograms that can reliably predict long-term outcomes.
A nomogram is an objective tool that uses an algorithm or mathematical formula to predict the probability of an outcome. Nomograms have been shown to outperform clinicians in predicting oncological outcomes and may be of benefit in certain decision-making settings. Nomograms can sift through the multitude of donor and recipient parameters that impact transplant outcome and help transplant physicians to better counsel their patients.
Using records from over 20,000 living donor transplant cases taken from the United Network for Organ Sharing (UNOS) registry, investigators from the Renal Transplantation Program, Glickman Urological & Kidney Institute at the Cleveland Clinic identified 18 characteristics, such as donor and recipient ages, donor serum creatinine levels and the cause of the recipient’s renal failure. By using the value of each factor to determine a point score and totaling all of the points, the nomograms were able to predict kidney function 1 year after transplant and 5-year transplant survival. By adding 3 additional factors obtained 6 months after surgery, another nomogram was developed to refine the 5-year survival prediction.
Writing in the article, D. A. Goldfarb states, “Our work is consistent with the transplant physician community’s efforts to develop better predictive tools...the nomograms developed in this study take this effort a step further by using a greater number of variables including early posttransplant information for better predictability and by attempting to predict specific outcome measures of renal function in addition to long term graft survival... These models can help to optimize the selection of living kidney donors. The prognostic information these models provide can help improve patient care.”
The article is “Nomograms for Predicting Graft Function and Survival in Living Donor Kidney Transplantation Based on the UNOS Registry” by H.Y. Tiong, D.A. Goldfarb, M.W. Kattan, J.M. Alster, L. Thuita, C. Yu, A. Wee and E.D. Poggio. It appears in The Journal of Urology, Volume 181, Issue 3 (March 2009) published by Elsevier.
# # #
Full text of the article featured above is available upon request. Contact Linda Gruner at (212) 633-3923 or email email@example.com to obtain a copy. To schedule an interview, contact Megan Ferington Pruce, Cleveland Clinic at (216) 445-7452 or firstname.lastname@example.org.
About The Journal of Urology®
Established in 1917, The Journal of Urology is the official journal of the American Urological Association. It is the most widely read and highly cited journal in the field. It brings to its readership all the clinically relevant information needed to stay at the forefront of this dynamic field. This top-ranking journal presents investigative studies on critical areas of research and practice, survey articles providing short condensations of the best and most important urology literature worldwide and practice-oriented reports on interesting clinical observations.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 212 633 3923